Etrasimod for ulcerative colitis: evaluating phase III results

Recent clinical trials have demonstrated efficacy and safety of etrasimod, a new sphingosine-1-phosphate receptor modulator, in the treatment of patients with moderately-to-severely active ulcerative colitis. Etrasimod is a promising new oral treatment option for ulcerative colitis, although long-term efficacy and safety data should be accumulated.

Automated summary

Recent clinical trials have shown that etrasimod, a new oral treatment for ulcerative colitis, is effective and safe for patients with moderately-to-severely active disease. However, more data on long-term efficacy and safety are needed before it can be widely recommended.